Zinc Chelator N,N,N′,N′-Tetrakis(2-Pyridylmethyl)Ethylenediamine Reduces the Resistance of Mycobacterium abscessus to Imipenem

References

• Swenson C, Zerbe CS, Fennelly K. Host variability in NTM disease: implications for research needs. Front Microbiol. 2018;9:2901. doi:10.3389/fmicb.2018.0290130559727
   PubMed Web of Science ®Google Scholar
• Hunt-Serracin AC, Parks BJ, Boll J, Boutte CC. Mycobacterium abscessus cells have altered antibiotic tolerance and surface glycolipids in artificial cystic fibrosis sputum medium. Antimicrob Agents Chemother. 2019;63:7. doi:10.1128/AAC.02488-18
   Web of Science ®Google Scholar
• Kwak N, Dalcolmo MP, Daley CL, et al. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J. 2019;54:1. doi:10.1183/13993003.01991-2018
   Web of Science ®Google Scholar
• Brown-Elliott BA, Wallace RJ Jr. In vitro susceptibility testing of bedaquiline against Mycobacterium abscessus complex. Antimicrob Agents Chemother. 2019;63:2.
   Web of Science ®Google Scholar
• Le Run E, Arthur M, Mainardi JL. In vitro and intracellular activity of imipenem combined with tedizolid, rifabutin, and avibactam against Mycobacterium abscessus. Antimicrob Agents Chemother. 2019;63(4). doi:10.1128/AAC.01915-18
   PubMed Web of Science ®Google Scholar
• Miyasaka T, Kunishima H, Komatsu M, et al. In vitro efficacy of imipenem in combination with six antimicrobial agents against Mycobacterium abscessus. Int J Antimicrob Agents. 2007;30(3):255–258. doi:10.1016/j.ijantimicag.2007.05.00317616451
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Rubio A, Wallace RJ Jr. In vitro susceptibility testing of a novel benzimidazole, SPR719, against Nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2018;62:11. doi:10.1128/AAC.01503-18
   Web of Science ®Google Scholar
• Cheng A, Tsai YT, Chang SY, et al. In vitro synergism of rifabutin with clarithromycin, imipenem, and tigecycline against the Mycobacterium abscessus complex. Antimicrob Agents Chemother. 2019;63:4. doi:10.1128/AAC.02234-18
   Web of Science ®Google Scholar
• Chua KYL, Bustamante A, Jelfs P, Chen SC-A, Sintchenko V. Antibiotic susceptibility of diverse Mycobacterium abscessus complex strains in New South Wales, Australia. Pathology. 2015;47(7):678–682. doi:10.1097/PAT.000000000000032726517625
   PubMed Web of Science ®Google Scholar
• Lee MC, Sun PL, Wu TL, et al. Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan. J Antimicrob Chemother. 2017;72(10):2782–2786. doi:10.1093/jac/dkx21229091186
   PubMed Web of Science ®Google Scholar
• Li B, Yang S, Chu H, et al. Relationship between antibiotic susceptibility and genotype in Mycobacterium abscessus clinical isolates. Front Microbiol. 2017;8:1739. doi:10.3389/fmicb.2017.0173928959242
   PubMed Web of Science ®Google Scholar
• Wachino J, Yamaguchi Y, Mori S, et al. Structural insights into recognition of hydrolyzed carbapenems and inhibitors by subclass B3 metallo-beta-lactamase SMB-1. Antimicrob Agents Chemother. 2016;60(7):4274–4282. doi:10.1128/AAC.03108-1527161644
   PubMed Web of Science ®Google Scholar
• Principe L, Vecchio G, Sheehan G, et al. Zinc chelators as carbapenem adjuvants for metallo-beta-lactamase-producing bacteria: in vitro and in vivo evaluation. Microb Drug Resist. 2020. doi:10.1089/mdr.2020.0037
   Web of Science ®Google Scholar
• Ye M, Xu L, Zou Y, et al. Molecular analysis of linezolid-resistant clinical isolates of Mycobacterium abscessus. Antimicrob Agents Chemother. 2019;63:2.
   Web of Science ®Google Scholar
• Gao Q, Wu S, Xu T, Zhao X, Huang H, Hu F. Emergence of carbapenem resistance in Bacteroides fragilis in China. Int J Antimicrob Agents. 2019;53(6):859–863. doi:10.1016/j.ijantimicag.2019.02.01730831235
   PubMed Web of Science ®Google Scholar
• Papp-Wallace KM, Bonomo RA. New beta-lactamase inhibitors in the clinic. Infect Dis Clin North Am. 2016;30(2):441–464. doi:10.1016/j.idc.2016.02.00727208767
   PubMed Web of Science ®Google Scholar
• Brown-Elliott BA, Killingley J, Vasireddy S, Bridge L, Wallace RJ Jr. In vitro comparison of ertapenem, meropenem, and imipenem against isolates of rapidly growing Mycobacteria and Nocardia by use of broth microdilution and etest. J Clin Microbiol. 2016;54(6):1586–1592. doi:10.1128/JCM.00298-1627053677
   PubMed Web of Science ®Google Scholar
• Jones LA, Doucette L, Dellon EP, Esther CR, McKinzie CJ. Use of inhaled imipenem/cilastatin in pediatric patients with cystic fibrosis: a case series. J Cyst Fibros. 2019;18(4):e42–e44. doi:10.1016/j.jcf.2019.04.01731060800
   PubMedGoogle Scholar
• Pandey R, Chen L, Manca C, et al. Dual beta-lactam combinations highly active against Mycobacterium abscessus complex in vitro. mBio. 2019;10(1). doi:10.1128/mBio.02895-18.
   PubMed Web of Science ®Google Scholar
• Rominski A, Schulthess B, Muller DM, Keller PM, Sander P. Effect of beta-lactamase production and beta-lactam instability on MIC testing results for. Mycobacterium Abscessus J Antimicrob Chemother. 2017;72(11):3070–3078. doi:10.1093/jac/dkx28428961987
   PubMed Web of Science ®Google Scholar
• Nordmann P, Poirel L. Emerging carbapenemases in gram-negative aerobes. Clin Microbiol Infect. 2002;8(6):321–331. doi:10.1046/j.1469-0691.2002.00401.x12084099
   PubMed Web of Science ®Google Scholar
• Leonardelli F, Macedo D, Dudiuk C, et al. In vitro activity of combinations of zinc chelators with amphotericin B and posaconazole against six Mucorales species. Antimicrob Agents Chemother. 2019;63:5. doi:10.1128/AAC.00266-19
   Web of Science ®Google Scholar
• Mayer LS, Uciechowski P, Meyer S, Schwerdtle T, Rink L, Haase H. Differential impact of zinc deficiency on phagocytosis, oxidative burst, and production of pro-inflammatory cytokines by human monocytes. Metallomics. 2014;6(7):1288–1295. doi:10.1039/c4mt0051j24823619
   PubMed Web of Science ®Google Scholar
• Hein KZ, Takahashi H, Tsumori T, et al. Disulphide-reduced psoriasin is a human apoptosis-inducing broad-spectrum fungicide. Proc Natl Acad Sci U S A. 2015;112(42):13039–13044. doi:10.1073/pnas.151119711226438863
   PubMed Web of Science ®Google Scholar
• Azumah R, Dutta J, Somboro AM, et al. In vitro evaluation of metal chelators as potential metallo-beta-lactamase inhibitors. J Appl Microbiol. 2016;120(4):860–867. doi:10.1111/jam.1308526849010
   PubMed Web of Science ®Google Scholar
• Laskaris P, Atrouni A, Calera JA, et al. Administration of zinc chelators improves survival of mice infected with Aspergillus fumigatus both in monotherapy and in combination with caspofungin. Antimicrob Agents Chemother. 2016;60(10):5631–5639. doi:10.1128/AAC.00324-1627401578
   PubMed Web of Science ®Google Scholar
• Adler M, Dinterman RE, Wannemacher RW. Protection by the heavy metal chelator N,N,N’,N’-tetrakis (2-pyridylmethyl)ethylenediamine (TPEN) against the lethal action of botulinum neurotoxin A and B. Toxicon. 1997;35(7):1089–1100. doi:10.1016/S0041-0101(96)00215-29248007
   PubMed Web of Science ®Google Scholar